Regeneron Pharmaceuticals (REGN) FCF Payout Ratio (2025 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly FCF Payout Ratio of 0.17 for Q2 2026, up 68.88% year-over-year from 0.1 in Q2 2025, and up 46.58% quarter-over-quarter from 0.12 in Q1 2026.
Regeneron Pharmaceuticals (REGN) FCF Payout Ratio (2025 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' FCF Payout Ratio history runs 2 years deep, the most recent figure standing at 0.17 for Q2 2026.
- In Q2 2026, FCF Payout Ratio rose 68.88% year-over-year to 0.17; the TTM figure through Jun 2026 stood at 0.08 (up 94.68% YoY), while the FY2025 annual figure was 0.08, changed N/A from the prior year.
- FCF Payout Ratio for Q2 2026 stood at 0.17, up from 0.12 in the prior quarter.
- The five-year high for FCF Payout Ratio was 0.17 in Q2 2026, with the low at 0.06 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.17 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.07 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.17 |
| Mar 31, 2026 | 0.12 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.11 |